LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
MF Mosele, A Lusque, V Dieras, E Deluche… - Annals of …, 2022 - annalsofoncology.org
Background T-DXd is an anti-HER2 antibody-drug conjugate that has demonstrated high
antitumor activity in HER2-positive and HER2-low metastatic breast cancer (mBC). We
aimed to unravel the mechanism of action and resistance to T-DXd in patients from DAISY
trial. Methods DAISY is a phase II clinical trial (NCT04132960) that assessed T-DXd efficacy
in mBC according to HER2-expression (HER2-positive, HER2-low, and HER2-negative).
Bystander effect and T-DXd uptake were analyzed by immunohistochemistry (IHC)(HER2 …
antitumor activity in HER2-positive and HER2-low metastatic breast cancer (mBC). We
aimed to unravel the mechanism of action and resistance to T-DXd in patients from DAISY
trial. Methods DAISY is a phase II clinical trial (NCT04132960) that assessed T-DXd efficacy
in mBC according to HER2-expression (HER2-positive, HER2-low, and HER2-negative).
Bystander effect and T-DXd uptake were analyzed by immunohistochemistry (IHC)(HER2 …
